姓名：徐艳萍

学位：博士

导师情况：博士生导师

研究领域：代谢物的感知与翻译后修饰调控肿瘤微环境

E-mail：yanpingxu@tongji.edu.cn

通讯地址：上海市杨浦区四平路1239号，同济大学生命科学与技术学院，200092

研究方向：

1. 代谢稳态调控信号转导和肿瘤细胞命运的机制研究 

2. 代谢物及蛋白质翻译后修饰调控肿瘤微环境的机制研究

3. 鉴定肿瘤治疗的新靶点及基于营养代谢干预的治疗策略探索

4. 去泛素化酶的底物筛选和生物学功能研究

个人简介：

 2010年毕业于厦门大学生命科学学院，获学士学位。2015年博士毕业于复旦大学生物化学与分子生物学专业，博士期间主要从事蛋白质翻译后修饰对肿瘤代谢的调控研究。2015年至2020年在美国北卡罗来纳大学教堂山分校Lineberger综合肿瘤中心做博士后研究，主要研究方向为蛋白质泛素化，表观遗传以及代谢小分子调控天然免疫和肿瘤免疫。2020年受聘于同济大学生命科学与技术学院任“青年百人计划”特聘研究员，兼任同济大学附属同济医院研究员。入选上海市海外高层次人才、东方学者特聘教授、青年科技启明星和浦江人才计划。获国自然面上项目、青年项目，国家重点研发计划，上海市面上项目等支持。

以通讯作者（含共同）在JCI, Science Advances, PNAS, Cell Reports, Cancer Research, Cell Discovery等重要学术期刊上发表研究论文20余篇，以第一作者（含共同）在Molecular Cell, JCI, Cell Reports, Cancer Research等学术期刊发表研究论文5篇。这些工作发表后受到了国内外同行的高度关注：著名期刊Nature Reviews Cancer, Cancer Discovery, JCI等杂志发表专题评述。以共同通讯作者发表于PNAS和以唯一通讯发表于Clin Transl Med 的论文入选ESI 高被引论文（引用前1%）。

本课题组设备齐全、经费充足；常年招聘博士后和研究生，欢迎博士生、硕士生、本科生报考和实习。

代表性论文（#Co-first author, *Co-corresponding author）：

2026年：

1. Du, Y., He, M., Xu, Y.X., Tian, T., Zhou, Y., Zhang, Y., Fu, H., Li, J., Lv, L.*, and Xu, Y.*(2026). AARS1-mediated lactylation of STAT1 drives immune evasion. Cell Rep 45,117094.

2. Cui, Z., Li, H., Liang, X., Zhao, X., Xu, K., Lu, Y., Zhang, Y., Li, X., Wu, S., Wang, Z.*, Lv, L.*, and Xu, Y.* (2026). AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastric cancer progression. Cell Death Dis 17, 363.

2025年：

1. Zhang, J., Tian, T., Li, X., Xu, K., Lu, Y., Li, X., Zhao, X., Cui, Z., Wang, Z., Zhou, Y., Xu, Y.X., Li, H., Zhang, Y., Du, Y., Lv, L., and Xu, Y.* (2025). p53 inhibits OTUD5 transcription to promote GPX4 degradation and induce ferroptosis in gastric cancer. Clin Transl Med 15, e70271. (ESI Highly cited paper)

2. Li, H., Zhang, X., Liang, X., Li, S., Cui, Z., Zhao, X., Wang, K., Zha, B., Ma, H.*, Xu, M.*, Lv, L.*, and Xu, Y.* (2025). HNF4α-TET2-FBP1 axis contributes to gluconeogenesis and type 2 diabetes. Elife 13, RP103663

3. Dai, Y., Li, H., Fan, S., Wang, K., Cui, Z., Zhao, X., Sun, X., Lin, M., Li, J., Gao, Y., Tian, Z., Yang, H.*, Zha, B.*, Lv, L.*, and Xu, Y.* (2025). Dimethyl fumarate promotes the degradation of HNF1B and suppresses the progression of clear cell renal cell carcinoma. Cell Death Dis 16, 71.

4. Gao, Y., Fan, S., Sun, X., Li, J., Dai, Y., Li, H.C., Ma, H.*, Xu, Y.*, and Lv, L.* (2025). Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma. Cell Death Dis 16, 432.

5. He, J., Lin, M., Teng, F., Sun, X., Tian, Z., Li, J., Ma, Y., Dai, Y., Gao, Y., Li, H., Tian, T., Xu, K.*, Li, X.*, Lv, L.*, and Xu, Y.* (2025). TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma. Cell Death Dis 16, 438.

6. Du, Y., Zhang, X., Xu, Y.X., Zhou, Y., and Xu, Y.* (2025). D-mannose suppresses the angiogenesis and progression of colorectal cancer. Acta Bioch Bioph Sin 57, 1270–1280.

7. Yin, X., Wu, J., Xu, M., Tian, T., Zhu, L., Wang, J., Dai, X., Yang, X., Qian, J., Wang, W., Zhu, L., Zhao, Z., Xu, K., Xu, Y.*, Li, X.*, and Hu, Z.* (2025). Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target. Mol Cancer 25, 44.

8. Zhang, Y., Liu, Z., Sun, H., Wang, Z., Chen, Y., Hu, Z., Li, X., Xu, K., Chen, Y., Xu, Y.*, Wang, C.*, and Xu, S.* (2025). Malignant epithelia cells-derived spermine induces APOE plus macrophages to suppress tumor immunity in adenocarcinoma of the esophagogastric junction. Front Med 12, 1636699.

2024年：

1. Dong, W., Lin, M., Zhang, R., Sun, X., Li, H., Liu, T.*, Xu, Y.*, and Lv, L.* (2024). D-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity. Cancer Lett 1, 216883.

2023年：

1. Lin, M., He, J., Zhang, X., Sun, X., Dong, W., Zhang, R., Xu, Y.*, and Lv, L.* (2023). Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. J Clin Invest 133. （Previewed by JCI, Editor’s picks）

2. Tian, T., Xie, X., Yi, W., Zhou, Y., Xu, Y., Wang, Z., Zhang, J., Lin, M., Zhang, R., Lv, Z., Li, X., Lv, L.*, Xu, Y.*. (2023). FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. Cell Rep 42,113362.

3. Sun, X., Dai, Y., He, J., Li, H., Yang, X., Dong, W., Xie, X., Wang, M., Xu, Y.*, and Lv, L.* (2023). D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC. Oncogene 42, 3503-3513.

4. He, J., Lin, M., Zhang, X., Zhang, R., Tian, T., Zhou, Y., Dong, W., Yang, Y., Sun, X., Dai, Y., Xu, Y., Zhang, Z., Xu, M., Lei, Q.Y., Xu, Y.*, and Lv, L.* (2023). TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential. Cell Discovery 9.

2022年：

1. Zhang, R., Yang, Y., Dong, W., Lin, M., He, J., Zhang, X., Tian, T., Yang, Y., Chen, K., Lei, Q.Y., Zhang, S.*, Xu, Y.*, and Lv, L.* (2022). D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A 119. (ESI Highly cited paper)

2. Zhang, X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., Lin, M., Yang, Y., Tian, T., Zhou, Y., Xu, Y., Lei, Q.Y., Zhang, J., Zhang, Q., Xu, Y.*, and Lv, L.* (2022). TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Cancer Res 82, 2097-2109.

3. Yi, W., Qiao, T., Yang, Z., Hu, L., Sun, M., Fan, H., Xu, Y.*, and Lv, Z.* (2022). The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis. Mater Today Bio 17, 100470

2021年之前

1. Chen, L.L., Smith, M.D., Lv, L., Nakagawa, T., Li, Z., Sun, S.C., Brown, N.G., Xiong, Y.*, and Xu, Y.* (2020). USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2. Sci Adv 6.

2. Xu, Y., Lv, L., Liu, Y., Smith, M.D., Li, W.C., Tan, X.M., Cheng, M., Li, Z., Bovino, M., Aube, J., Xiong, Y.* (2019). Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest 129, 4316-4331.

3. Lv, L.#, Wang, Q.#, Xu, Y.#, Tsao, L.C.#, Nakagawa, T., Guo, H., Su, L.*, and Xiong, Y.* (2018). Vpr Targets TET2 for Degradation by CRL4(VprBP) E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1 Replication. Mol Cell 70, 961-970 e965.

4. Murphy, C.M.#, Xu, Y.#, Li, F.#, Nio, K., Reszka-Blanco, N., Li, X., Wu, Y., Yu, Y., Xiong, Y.*, and Su, L.* (2016). Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Rep 16, 2846-2854.

5. Xu, Y., Li, F., Lv, L., Li, T., Zhou, X., Deng, C.X., Guan, K.L., Lei, Q.Y.*, and Xiong, Y.* (2014). Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res 74, 3630-3642.

6. Lv, L.#, Xu, Y.#, Zhao, D., Li, F.L., Wang, W., Sasaki, N., Jiang, Y., Zhou, X., Li, T.T., Guan, K.L., Lei, Q.Y.*, and Xiong, Y.* (2013). Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell 52, 340-352. (Cover Story, Highlighted by Nature Reviews Cancer and Cancer Discovery)